Abstract
Due to the increased effectiveness of oncology treatments, cardiovascular disease, including chronic heart failure, is a major cause of morbidity and mortality in cancer survivors, limiting their life expectancy. Screening of 4700 literary sources from the databases "Scopus", "Web of Science", "PubMed / MedLine", "The CochraneLibrary" was carried out for the keywords "anthracycline-induced cardiotoxicity", "cardiooncology", "cancer therapy-related cardiac dysfunction", "sacubitril/valsartan" for the last 10 years. The review, based on the analysis of highly cited articles, outlines the current understanding of the cardiotoxicity of anthracyclines, its mechanisms and possibilities for correction, including the use of sacubitril/valsartan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
